AMC Stock Forecast, How High Could It Go in 2025 and Beyond?
AMC Entertainment (NYSE:AMC) has been rising lately after years of…
Sell
48
LH Quote, Financials, Valuation and Earnings
Last price:
$261.34
Seasonality move
:
1.55%
Day range:
$259.03 - $262.99
52-week range:
$198.96 - $264.03
Dividend yield:
1.11%
P/E ratio:
29.99x
P/S ratio:
1.66x
P/B ratio:
2.61x
Volume:
659.5K
Avg. volume:
681.9K
1-year change:
28.72%
Market cap:
$21.7B
Revenue:
$13B
EPS (TTM):
$8.65
Analysts' Opinion
-
Consensus RatingLabcorp Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $275.84, Labcorp Holdings has an estimated upside of 5.85% from its current price of $259.45.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $248.00 representing 4.41% downside risk from its current price of $259.45.
Fair Value
-
According to the consensus of 17 analysts, Labcorp Holdings has 5.85% upside to fair value with a price target of $275.84 per share.
LH vs. S&P 500
-
Over the past 5 trading days, Labcorp Holdings has overperformed the S&P 500 by 1.08% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Labcorp Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Labcorp Holdings has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Labcorp Holdings reported revenues of $3.3B.
Earnings Growth
-
Labcorp Holdings earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Labcorp Holdings reported earnings per share of $2.52.
Enterprise value:
26.9B
EV / Invested capital:
1.94x
Price / LTM sales:
1.66x
EV / EBIT:
23.32x
EV / Revenue:
2.04x
PEG ratio (5yr expected):
0.40x
EV / Free cash flow:
23.38x
Price / Operating cash flow:
18.98x
Enterprise value / EBITDA:
14.87x
Gross Profit (TTM):
$3.7B
Return On Assets:
4.16%
Net Income Margin (TTM):
5.55%
Return On Equity:
9.01%
Return On Invested Capital:
5.27%
Operating Margin:
9.94%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $11.8B | $12.3B | $13.2B | $3.2B | $3.3B | |
| Gross Profit | $3.5B | $3.4B | $3.7B | $897.3M | $948M | |
| Operating Income | $1.5B | $1.1B | $1.1B | $328.8M | $332.4M | |
| EBITDA | $1.7B | $1.4B | $1.8B | $498.8M | $498M | |
| Diluted EPS | $11.02 | $4.95 | $8.65 | $2.69 | $2.52 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $5.6B | $5.2B | $4.7B | $3.5B | $3.8B | |
| Total Assets | $20.4B | $20.7B | $20.2B | $16.5B | $17.6B | |
| Current Liabilities | $3.4B | $2.6B | $2.9B | $3.9B | $2.1B | |
| Total Liabilities | $10.4B | $10B | $9.8B | $8.6B | $9.3B | |
| Total Equity | $10B | $10.7B | $10.4B | $8B | $8.3B | |
| Total Debt | $5.4B | $5.4B | $5.4B | $5.1B | $5.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.7B | $1.2B | $1.6B | -$29.8M | $18.5M | |
| Cash From Investing | -$1.2B | -$1.5B | -$1.3B | -$393.1M | -$336M | |
| Cash From Financing | -$1.4B | -$10.4M | -$48.1M | -$11.7M | -$839.7M | |
| Free Cash Flow | $1.3B | $667.5M | $1.2B | -$163.6M | -$107.5M | |
LH
Sector
Market Cap
$21.7B
$32.6M
Price % of 52-Week High
98.27%
47.07%
Dividend Yield
1.11%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
28.72%
-37.62%
Beta (5-Year)
0.812
0.632
Dividend yield:
1.11%
Annualized payout:
$2.88
Payout ratio:
33.2%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$259.40
200-day SMA
Buy
Level
$235.83
Bollinger Bands (100)
Buy
Level
231.56 - 253.64
Chaikin Money Flow
Buy
Level
335.3M
20-day SMA
Buy
Level
$252.35
Relative Strength Index (RSI14)
Buy
Level
61.53
ADX Line
Buy
Level
16.83
Williams %R
Neutral
Level
-22.5394
50-day SMA
Buy
Level
$241.68
MACD (12, 26)
Buy
Level
5.18
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
233M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.7591)
Buy
CA Score
(Annual)
Level (-0.0868)
Buy
Beneish M-Score
(Annual)
Level (-2.7378)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-0.8298)
Buy
Piotroski F Score
(Annual)
Level (8)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Stock Forecast FAQ
In the current month, LH has received 13 Buy ratings 4 Hold ratings, and 0 Sell ratings. The LH average analyst price target in the past 3 months is $275.84.
-
Where Will Labcorp Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Labcorp Holdings share price will rise to $275.84 per share over the next 12 months.
-
What Do Analysts Say About Labcorp Holdings?
Analysts are divided on their view about Labcorp Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Labcorp Holdings is a Sell and believe this share price will drop from its current level to $248.00.
-
What Is Labcorp Holdings's Price Target?
The price target for Labcorp Holdings over the next 1-year time period is forecast to be $275.84 according to 17 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is LH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Labcorp Holdings is a Buy. 13 of 17 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LH?
You can purchase shares of Labcorp Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Labcorp Holdings shares.
-
What Is The Labcorp Holdings Share Price Today?
Labcorp Holdings was last trading at $261.34 per share. This represents the most recent stock quote for Labcorp Holdings. Yesterday, Labcorp Holdings closed at $259.45 per share.
-
How To Buy Labcorp Holdings Stock Online?
In order to purchase Labcorp Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Reddit Stock Be In 5 Years?
On a wet March morning last year, the famously orange…
Will Palantir Crash?
AI and data analytics software major Palantir (NASDAQ:PLTR) has been…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
47
RGC alert for Jun 18
Regencell Bioscience Holdings [RGC] is down 18.36% over the past day.
Sell
20
ENPH alert for Jun 18
Enphase Energy [ENPH] is up 4.18% over the past day.
Sell
49
QNTM alert for Jun 18
Quantum BioPharma [QNTM] is up 17.61% over the past day.
